摘要
目的观察依达拉奉注射液联合疏血通注射液治疗急性脑出血的疗效。方法将120例急性脑出血患者随机分为观察组和对照1,2,3组,各30例。观察组在常规治疗基础上加用疏血通注射液6 m L(每天1次静脉滴注)及依达拉奉注射液30 mg(每天2次静脉滴注),连用14 d;对照1组给予脑出血常规治疗;对照2组给予脑出血常规治疗加疏血通注射液6 m L(每天1次静脉滴注);对照3组给予脑出血常规治疗加依达拉奉注射液30 mg(每天2次静脉滴注);于治疗前及治疗第10天、第20天,复查头颅CT观察血肿大小,用美国国立卫生研究院卒中量表(NIHSS)评价两组神经功能缺损情况。结果治疗第10天、第20天,观察组NIHSS评分降幅、血肿体积减少量明显大于3个对照组(P<0.05);日常生活能力(BI指数)评分均明显优于各对照组(P<0.05)。结论疏血通注射液联合依达拉奉注射液治疗急性脑出血具有协同作用,可加快血肿吸收,促进神经功能恢复,且较两药单独使用时更具优势,值得临床推广。
Objective To investigate the clinical efficacy of Edaravone Injection combined with Shuxuetong Injection in the treatment of acute cerebral hemorrhage.Methods 120 cases of acute cerebral hemorrhage were randomly divided into observation group and control groups 1,2 and 3;30 cases in the observation group were given routine treatment combined with Shuxuetong Injection（6 mL intravenously once daily） and Edaravone Injection（30 mg intravenous drip,two times daily） for 14 d;30 cases in the control group 1were treated with routine treatment of cerebral hemorrhage;30 cases in the control group 2 were given conventional treatment combined with Shuxuetong Injection（6 mL intravenously,once daily）;30 cases in the control group 3 were given conventional treatment of cerebral hemorrhage combined with Edaravone Injection 30 mg contains injection（30 mg intravenously,two times daily）.CT observation of hematoma volume was reviewed before treatment,at the 10 th,and 20 th day after treatment;the nerve function defect of the two groups were assessed by the National Institutes of Health Stroke Scale（NIHSS）.Results On the 10 th and 20 th day of treatment,the decrease of NIHSS score and hematoma volume in the observation group were significantly greater than those in the control group（P〈0.05）and the score of the daily living ability（BI index） were significantly better than those in the control group（P〈0.05）.Conclusion Shuxue—tong Injection combined with Edaravone Injection has synergistic efficacy on acute cerebral hemorrhage.It can accelerate the absorption of hematoma and promote the recovery of nerve function,which is more worthy of clinical application than using the two drugs separately.
出处
《中国药业》
CAS
2016年第22期44-47,共4页
China Pharmaceuticals
